Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies

Anticancer immunotherapies, such as immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells, have improved outcomes for patients with a variety of malignancies. However, most patients either do not initially respond or do not exhibit durable responses due to primary or adaptive/acquired immune resistance mechanisms of the tumor microenvironment. These suppressive programs are myriad, different between patients with ostensibly the same cancer type, and can harness multiple cell types to reinforce their stability. Consequently, the overall benefit of monotherapies remains limited. Cutting-edge technologies now allow for extensive tumor profiling, which can be used to define tumor cell intrinsic and extrinsic pathways of primary and/or acquired immune resistance, herein referred to as features or feature sets of immune resistance to current therapies. We propose that cancers can be characterized by immune resistance archetypes, comprised of five feature sets encompassing known immune resistance mechanisms. Archetypes of resistance may inform new therapeutic strategies that concurrently address multiple cell axes and/or suppressive mechanisms, and clinicians may consequently be able to prioritize targeted therapy combinations for individual patients to improve overall efficacy and outcomes.

[1]  Ajit S. Divakaruni,et al.  A practical guide for the analysis, standardization and interpretation of oxygen consumption measurements , 2022, Nature Metabolism.

[2]  E. D. de Vries,et al.  Molecular imaging to support cancer immunotherapy , 2022, Journal for ImmunoTherapy of Cancer.

[3]  R. Vento-Tormo,et al.  An introduction to spatial transcriptomics for biomedical research , 2022, Genome Medicine.

[4]  C. Lausted,et al.  Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases , 2022, Gut.

[5]  M. Pittet,et al.  Author Correction: Clinical relevance of tumour-associated macrophages , 2022, Nature Reviews Clinical Oncology.

[6]  Congmin Xu,et al.  Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors , 2022, Nature Biomedical Engineering.

[7]  J. C. Love,et al.  Mitochondrial variant enrichment from high-throughput single-cell RNA sequencing resolves clonal populations , 2022, Nature Biotechnology.

[8]  U. Hofmann,et al.  T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10 , 2022, Nature communications.

[9]  M. Moseley,et al.  In vivo imaging of nanoparticle-labeled CAR T cells , 2022, Proceedings of the National Academy of Sciences.

[10]  J. Pearson,et al.  Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. , 2021, Cancer cell.

[11]  J. Wolchok,et al.  CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody , 2021, The Journal of Nuclear Medicine.

[12]  R. Boellaard,et al.  PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer , 2021, The Journal of Nuclear Medicine.

[13]  S. Schuster,et al.  Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices , 2021, Nature Methods.

[14]  V. Pillarisetty,et al.  Protocol for tissue slice cultures from human solid tumors to study therapeutic response , 2021, STAR protocols.

[15]  T. Mempel,et al.  Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop , 2021, Cell.

[16]  Jincui Gu,et al.  PTEN loss correlates with T cell exclusion across human cancers , 2021, BMC cancer.

[17]  Thomas D. Wu,et al.  Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade , 2021, Journal for ImmunoTherapy of Cancer.

[18]  Y. Saeys,et al.  Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization , 2021, Nature Neuroscience.

[19]  Steven L. Chang,et al.  Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. , 2021, Cancer cell.

[20]  J. Linton,et al.  Building the Next Generation of Humanized Hemato-Lymphoid System Mice , 2021, Frontiers in Immunology.

[21]  A. Elorza,et al.  CD73 Ectonucleotidase Restrains CD8+ T Cell Metabolic Fitness and Anti-tumoral Activity , 2021, Frontiers in Cell and Developmental Biology.

[22]  Zhijie Xu,et al.  Applying artificial intelligence for cancer immunotherapy , 2021, Acta pharmaceutica Sinica. B.

[23]  K. Livak,et al.  Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy , 2020, Nature Reviews Clinical Oncology.

[24]  R. Mach,et al.  PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response , 2020, Molecules.

[25]  Y. Najjar,et al.  Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations , 2020, Cancers.

[26]  Tao Wang,et al.  DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. , 2020, Cancer cell.

[27]  Henry W. Long,et al.  Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer , 2020, Cancer Research.

[28]  Ashton C. Berger,et al.  Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma , 2020, Nature Medicine.

[29]  Noam Shental,et al.  The human tumor microbiome is composed of tumor type–specific intracellular bacteria , 2020, Science.

[30]  D. Guan,et al.  Glycolysis and Oxidative Phosphorylation Play Critical Roles in Natural Killer Cell Receptor-Mediated Natural Killer Cell Functions , 2020, Frontiers in Immunology.

[31]  M. Neidert,et al.  Tumor-Specific T Cell Activation in Malignant Brain Tumors , 2020, Frontiers in Immunology.

[32]  A. Iwasaki,et al.  VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours , 2020, Nature.

[33]  P. Hegde,et al.  Top 10 Challenges in Cancer Immunotherapy. , 2020, Immunity.

[34]  Zev A. Binder,et al.  A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity , 2019, Cell.

[35]  D. Powell,et al.  An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer. , 2019, Gynecologic oncology.

[36]  T. Thomas,et al.  Fluorescence in situ hybridization (FISH) and cell sorting of living bacteria , 2019, Scientific Reports.

[37]  Heeva Baharlou,et al.  Mass Cytometry Imaging for the Study of Human Diseases—Applications and Data Analysis Strategies , 2019, Front. Immunol..

[38]  Garry Nolan,et al.  MIBI-TOF: A multiplexed imaging platform relates cellular phenotypes and tissue structure , 2019, Science Advances.

[39]  E. Wherry,et al.  Defining ‘T cell exhaustion’ , 2019, Nature Reviews Immunology.

[40]  Cheryl F. Lichti,et al.  MHC-II neoantigens shape tumor immunity and response to immunotherapy , 2019, Nature.

[41]  William A. Walters,et al.  Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2 , 2019, Nature Biotechnology.

[42]  Jason D. Buenrostro,et al.  Droplet-based combinatorial indexing for massive-scale single-cell chromatin accessibility , 2019, Nature Biotechnology.

[43]  Ash A. Alizadeh,et al.  Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.

[44]  Chun Jimmie Ye,et al.  Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity , 2019, Cell.

[45]  F. Hodi,et al.  Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade , 2019, Nature Immunology.

[46]  P. Catalano,et al.  irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial , 2019, Clinical Cancer Research.

[47]  S. Sidhu,et al.  Humanized Mice for the Study of Immuno-Oncology. , 2018, Trends in immunology.

[48]  M. Antoniewicz.  A guide to 13C metabolic flux analysis for the cancer biologist , 2018, Experimental & Molecular Medicine.

[49]  Y. Kluger,et al.  A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies , 2018, Nature Communications.

[50]  Camille Stephan-Otto Attolini,et al.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.

[51]  Chun Jimmie Ye,et al.  Multiplexed droplet single-cell RNA-sequencing using natural genetic variation , 2017, Nature Biotechnology.

[52]  W. Brenner,et al.  Approaches and techniques to characterize cancer metabolism in vitro and in vivo. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[53]  Angela E. Leek,et al.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.

[54]  C. Uyttenhove,et al.  Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes , 2017, Nature Communications.

[55]  C. Marosi,et al.  Correlation of immune phenotype with IDH mutation in diffuse glioma , 2017, Neuro-oncology.

[56]  M. Donia,et al.  Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model , 2017, Nature Communications.

[57]  H. Swerdlow,et al.  Large-scale simultaneous measurement of epitopes and transcriptomes in single cells , 2017, Nature Methods.

[58]  C. Tropini,et al.  The Gut Microbiome: Connecting Spatial Organization to Function. , 2017, Cell host & microbe.

[59]  Adam A. Margolin,et al.  Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. , 2017, Cell reports.

[60]  David K. Finlay,et al.  What Fuels Natural Killers? Metabolism and NK Cell Responses , 2017, Front. Immunol..

[61]  John R. Haliburton,et al.  Abseq: Ultrahigh-throughput single cell protein profiling with droplet microfluidic barcoding , 2017, Scientific Reports.

[62]  D. Quail,et al.  The Microenvironmental Landscape of Brain Tumors. , 2017, Cancer cell.

[63]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.

[64]  L. Fong,et al.  3D: diversity, dynamics, differential testing – a proposed pipeline for analysis of next-generation sequencing T cell repertoire data , 2017, BMC Bioinformatics.

[65]  Todd M. Allen,et al.  The epigenetic landscape of T cell exhaustion , 2016, Science.

[66]  S. Haferkamp,et al.  LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. , 2016, Cell metabolism.

[67]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[68]  Simon C Watkins,et al.  The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. , 2016, Immunity.

[69]  Matheus C. Bürger,et al.  Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy , 2016, Nature.

[70]  Grace X. Y. Zheng,et al.  Massively parallel digital transcriptional profiling of single cells , 2016, Nature Communications.

[71]  Jun S. Liu,et al.  Landscape of tumor-infiltrating T cell repertoire of human cancers , 2016, Nature Genetics.

[72]  Justin L Sonnenburg,et al.  Quantitative Imaging of Gut Microbiota Spatial Organization. , 2015, Cell host & microbe.

[73]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[74]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[75]  R. DeMatteo,et al.  Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T , 2015, Cancer Immunology, Immunotherapy.

[76]  A. Palucka,et al.  Development and function of human innate immune cells in a humanized mouse model , 2014, Nature Biotechnology.

[77]  Åsa K. Björklund,et al.  Full-length RNA-seq from single cells using Smart-seq2 , 2014, Nature Protocols.

[78]  Jason B. Williams,et al.  Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.

[79]  D. Bigner,et al.  Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. , 2013, Future oncology.

[80]  M. Wendland,et al.  MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles , 2011, Clinical Cancer Research.

[81]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[82]  S. Abbott,et al.  16S rRNA Gene Sequencing for Bacterial Identification in the Diagnostic Laboratory: Pluses, Perils, and Pitfalls , 2007, Journal of Clinical Microbiology.

[83]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[84]  David J. Yang,et al.  The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. , 2006, Neuro-oncology.

[85]  Arend Heerschap,et al.  Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy , 2005, Nature Biotechnology.

[86]  M. McGuckin,et al.  Mucins : methods and protocols , 2012 .

[87]  M. Johansson,et al.  Preservation of mucus in histological sections, immunostaining of mucins in fixed tissue, and localization of bacteria with FISH. , 2012, Methods in molecular biology.

[88]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[89]  L. S. Cram,et al.  Flow cytometry, an overview. , 2002, Methods in cell science : an official journal of the Society for In Vitro Biology.